Clinical Efficiency of Rituximab Combined with Autologous Hematopoietic Blood Stem Cell Transplantation for Treatment of CD20
10.19746/j.cnki.issn.1009-2137.2021.01.013
- Author:
Qian Jin YU
1
;
Yong Sheng CHEN
2
;
Dong Feng ZENG
3
;
Jia Li LI
3
;
Li Dan ZHU
3
;
Lei GAO
3
;
Li GAO
3
;
Yao LIU
3
;
Xiao Lin YIN
4
;
Xi ZHANG
3
;
Pei Yan KONG
5
Author Information
1. Medical Center for Hematology, Second Affiliated Hospital of Army Medical University，Chongqing 400037,Department of Hematology, Linyi People's Hospital, Dezhou 251500, Shandong Province, China.
2. Medical Center for Hematology, Second Affiliated Hospital of Army Medical University，Chongqing 400037,Department of Hematology, the 923th Hospital of the People's Liberation Army Joint Service Support Force, Nanning 530021, Guangxi Zhuang Autonomous Region, China.
3. Medical Center for Hematology, Second Affiliated Hospital of Army Medical University，Chongqing 400037.
4. Department of Hematology, the 923th Hospital of the People's Liberation Army Joint Service Support Force, Nanning 530021, Guangxi Zhuang Autonomous Region, China.
5. Medical Center for Hematology, Second Affiliated Hospital of Army Medical University，Chongqing 400037,E.mail：peiyankong@163.com.
- Publication Type:Journal Article
- MeSH:
Antineoplastic Combined Chemotherapy Protocols;
Disease-Free Survival;
Hematopoietic Stem Cell Transplantation;
Hodgkin Disease;
Humans;
Lymphoma, Non-Hodgkin/drug therapy*;
Rituximab/therapeutic use*;
Transplantation, Autologous;
Treatment Outcome
- From:
Journal of Experimental Hematology
2021;29(1):77-85
- CountryChina
- Language:Chinese
-
Abstract:
METHODS:From January 2005 to December 2013, 83 patients with refractory/recurrent CD20
RESULTS:All the patient achieved complete response. The median follow.up time was 39 months. Both the two groups collected peripheral blood stem cells successfully, and had no difference in hematopoietic reconstitution time. Three patients in treatment group and six patients in control group relapsed and the three year overall survival and EFS in treatment group was significantly higher than that in control group, that is（93.0% vs 73.1%, P=0.037） and （89.5% vs 65.4%, P=0.034）, respectively. Subgroup analysis showed that: compared with the treatment group in which using R in the whole courses(before and after transplantation, and collection of stem cells) was superior to the control group in both OS and EFS, with the OS 97% vs 87.5% (P>0.05) and EFS 97% vs 76.2% (P=0.05) respectively. While stratified by the different courses of rituximab, the OS was 88.9% (1-2 courses, 9 cases), 93.1% (3-4 courses, 29 cases), 94.7%(more than 5 courses,19 cases), and EFS was 77.8%, 89.7% and 94.7%, respectively.
CONCLUSION:For the patients with refractory/recurrent CD20
